{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T18:43:43Z","timestamp":1784141023234,"version":"3.55.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2010,12,31]],"date-time":"2010-12-31T00:00:00Z","timestamp":1293753600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1007\/s00702-010-0573-6","type":"journal-article","created":{"date-parts":[[2010,12,30]],"date-time":"2010-12-30T12:37:04Z","timestamp":1293712624000},"page":"865-875","source":"Crossref","is-referenced-by-count":85,"title":["Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington\u2019s disease"],"prefix":"10.1007","volume":"118","author":[{"given":"D\u00e9nes","family":"Z\u00e1dori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e1bor","family":"Nyiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e1s","family":"Sz\u0151nyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istv\u00e1n","family":"Szatm\u00e1ri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferenc","family":"F\u00fcl\u00f6p","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f3zsef","family":"Toldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s F.","family":"Freund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3","family":"V\u00e9csei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Kliv\u00e9nyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,12,31]]},"reference":[{"key":"573_CR1","doi-asserted-by":"crossref","first-page":"C1075","DOI":"10.1152\/ajpcell.00619.2004","volume":"289","author":"A Bahn","year":"2005","unstructured":"Bahn A, Ljubojevic M, Lorenz H, Schultz C, Ghebremedhin E, Ugele B, Sabolic I, Burckhardt G, Hagos Y (2005) Murine renal organic anion transporters mOAT1 and mOAT3 facilitate the transport of neuroactive tryptophan metabolites. Am J Physiol Cell Physiol 289:C1075\u2013C1084","journal-title":"Am J Physiol Cell Physiol"},{"key":"573_CR2","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1111\/j.1471-4159.1990.tb03143.x","volume":"55","author":"MF Beal","year":"1990","unstructured":"Beal MF, Matson WR, Swartz KJ, Gamache PH, Bird ED (1990) Kynurenine pathway measurements in Huntington\u2019s disease striatum: evidence for reduced formation of kynurenic acid. J Neurochem 55:1327\u20131339","journal-title":"J Neurochem"},{"key":"573_CR3","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0014-2999(88)90814-X","volume":"151","author":"PJ Birch","year":"1988","unstructured":"Birch PJ, Grossman CJ, Hayes AG (1988) Kynurenate and FG9041 have both competitive and non-competitive antagonist actions at excitatory amino acid receptors. Eur J Pharmacol 151:313\u2013315","journal-title":"Eur J Pharmacol"},{"key":"573_CR4","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.bmcl.2006.10.033","volume":"17","author":"I Borza","year":"2007","unstructured":"Borza I, Kolok S, Galg\u00f3czy K, Gere A, Horv\u00e1th C, Farkas S, Greiner I, Dom\u00e1ny G (2007) Kynurenic acid amides as novel NR2B selective NMDA receptor antagonists. Bioorg Med Chem Lett 17:406\u2013409","journal-title":"Bioorg Med Chem Lett"},{"key":"573_CR5","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1046\/j.1471-4159.1999.0721890.x","volume":"72","author":"N Chen","year":"1999","unstructured":"Chen N, Luo T, Wellington C, Metzler M, McCutcheon K, Hayden MR, Raymond LA (1999) Subtype-specific enhancement of NMDA receptor currents by mutant huntingtin. J Neurochem 72:1890\u20131898","journal-title":"J Neurochem"},{"key":"573_CR6","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1476-5381.1988.tb11474.x","volume":"93","author":"JH Connick","year":"1988","unstructured":"Connick JH, Stone TW (1988) Quinolinic acid effects on amino acid release from the rat cerebral cortex in vitro and in vivo. Br J Pharmacol 93:868\u2013876","journal-title":"Br J Pharmacol"},{"key":"573_CR7","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/263244a0","volume":"263","author":"JT Coyle","year":"1976","unstructured":"Coyle JT, Schwarcz R (1976) Lesion of striatal neurons with kainic acid provides a model for Huntington\u2019s chorea. Nature 263:244\u2013246","journal-title":"Nature"},{"key":"573_CR8","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1006\/exnr.2002.7973","volume":"177","author":"A Csillik","year":"2002","unstructured":"Csillik A, Knyih\u00e1r E, Okuno E, Krisztin-P\u00e9va B, Csillik B, V\u00e9csei L (2002) Effect of 3-nitropropionic acid on kynurenine aminotransferase in rat brain. Exp Neurol 177:233\u2013241","journal-title":"Exp Neurol"},{"key":"573_CR9","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/0197-0186(95)00091-7","volume":"28","author":"LP Carvalho de","year":"1996","unstructured":"de Carvalho LP, Bochet P, Rossier J (1996) The endogenous agonist quinolinic acid and the non endogenous homoquinolinic acid discriminate between NMDAR2 receptor subunits. Neurochem Int 28:445\u2013452","journal-title":"Neurochem Int"},{"key":"573_CR10","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/0166-2236(90)90111-M","volume":"13","author":"M DiFiglia","year":"1990","unstructured":"DiFiglia M (1990) Excitotoxic injury of the neostriatum: a model for Huntington\u2019s disease. Trends Neurosci 13:286\u2013289","journal-title":"Trends Neurosci"},{"key":"573_CR11","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1523\/JNEUROSCI.22-05-01592.2002","volume":"22","author":"RJ Ferrante","year":"2002","unstructured":"Ferrante RJ, Andreassen OA, Dedeoglu A, Ferrante KL, Jenkins BG, Hersch SM, Beal MF (2002) Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington\u2019s disease. J Neurosci 22:1592\u20131599","journal-title":"J Neurosci"},{"key":"573_CR12","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/0306-4522(81)90168-8","volume":"6","author":"F Fonnum","year":"1981","unstructured":"Fonnum F, Storm-Mathisen J, Divac I (1981) Biochemical evidence for glutamate as neurotransmitter in corticostriatal and corticothalamic fibres in rat brain. Neuroscience 6:863\u2013873","journal-title":"Neuroscience"},{"key":"573_CR13","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1111\/j.1471-4159.1991.tb03460.x","volume":"56","author":"S Fukui","year":"1991","unstructured":"Fukui S, Schwarcz R, Rapoport SI, Takada Y, Smith OR (1991) Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem 56:2007\u20132017","journal-title":"J Neurochem"},{"key":"573_CR14","doi-asserted-by":"crossref","first-page":"4828","DOI":"10.2174\/092986709789909602","volume":"16","author":"F F\u00fcl\u00f6p","year":"2009","unstructured":"F\u00fcl\u00f6p F, Szatm\u00e1ri I, V\u00e1mos E, Z\u00e1dori D, Toldi J, V\u00e9csei L (2009) Synthesis, transformations and pharmaceutical applications of kynurenic acid derivatives. Curr Med Chem 16:4828\u20134842","journal-title":"Curr Med Chem"},{"key":"573_CR15","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1523\/JNEUROSCI.19-04-01189.1999","volume":"19","author":"FR Fusco","year":"1999","unstructured":"Fusco FR, Chen Q, Lamoreaux WJ, Figueredo-Cardenas G, Jiao Y, Coffman JA, Surmeier DJ, Honig MG, Carlock LR, Reiner A (1999) Cellular localization of huntingtin in striatal and cortical neurons in rats: lack of correlation with neuronal vulnerability in Huntington\u2019s disease. J Neurosci 19:1189\u20131202","journal-title":"J Neurosci"},{"key":"573_CR16","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s00702-004-0201-4","volume":"111","author":"G G\u00e1rdi\u00e1n","year":"2004","unstructured":"G\u00e1rdi\u00e1n G, V\u00e9csei L (2004) Huntington\u2019s disease: pathomechanism and therapeutic perspectives. J Neural Transm 111:1485\u20131494","journal-title":"J Neural Transm"},{"key":"573_CR17","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1074\/jbc.M410210200","volume":"280","author":"G G\u00e1rdi\u00e1n","year":"2005","unstructured":"G\u00e1rdi\u00e1n G, Browne SE, Choi DK, Kliv\u00e9nyi P, Gregorio J, Kubilus JK, Ryu H, Langley B, Ratan RR, Ferrante RJ, Beal MF (2005) Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington\u2019s disease. J Biol Chem 280:556\u2013563","journal-title":"J Biol Chem"},{"key":"573_CR18","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.nbd.2004.07.006","volume":"17","author":"P Guidetti","year":"2004","unstructured":"Guidetti P, Luthi-Carter RE, Augood SJ, Schwarcz R (2004) Neostriatal and cortical quinolinate levels are increased in early grade Huntington\u2019s disease. Neurobiol Dis 17:455\u2013461","journal-title":"Neurobiol Dis"},{"key":"573_CR19","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.nbd.2006.02.011","volume":"23","author":"P Guidetti","year":"2006","unstructured":"Guidetti P, Bates GP, Graham RK, Hayden MR, Leavitt BR, MacDonald ME, Slow EJ, Wheeler VC, Woodman B, Schwarcz R (2006) Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. Neurobiol Dis 23:190\u2013197","journal-title":"Neurobiol Dis"},{"key":"573_CR20","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/sj.bjp.0701834","volume":"124","author":"CA Harris","year":"1998","unstructured":"Harris CA, Miranda AF, Tanguay JJ, Boegman RJ, Beninger RJ, Jhamandas K (1998) Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid. Br J Pharmacol 124:391\u2013399","journal-title":"Br J Pharmacol"},{"key":"573_CR21","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1523\/JNEUROSCI.5599-08.2009","volume":"29","author":"MY Heng","year":"2009","unstructured":"Heng MY, Detloff PJ, Wang PL, Tsien JZ, Albin RL (2009) In vivo evidence for NMDA receptor-mediated excitotoxicity in a murine genetic model of Huntington disease. J Neurosci 29:3200\u20133205","journal-title":"J Neurosci"},{"key":"573_CR22","doi-asserted-by":"crossref","first-page":"7463","DOI":"10.1523\/JNEUROSCI.21-19-07463.2001","volume":"21","author":"C Hilmas","year":"2001","unstructured":"Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX (2001) The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci 21:7463\u20137473","journal-title":"J Neurosci"},{"key":"573_CR23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0022-510X(94)00280-2","volume":"130","author":"D Jauch","year":"1995","unstructured":"Jauch D, Urba\u0144ska EM, Guidetti P, Bird ED, Vonsattel JP, Whetsell WO Jr, Schwarcz R (1995) Dysfunction of brain kynurenic acid metabolism in Huntington\u2019s disease: focus on kynurenine aminotransferases. J Neurol Sci 130:39\u201347","journal-title":"J Neurol Sci"},{"key":"573_CR24","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1111\/j.1471-4159.1989.tb01881.x","volume":"52","author":"M Kessler","year":"1989","unstructured":"Kessler M, Terramani T, Lynch G, Baudry M (1989) A glycine site associated with N-methyl-d-aspartic acid receptors: characterization and identification of a new class of antagonists. J Neurochem 52:1319\u20131328","journal-title":"J Neurochem"},{"key":"573_CR25","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.bbr.2006.01.003","volume":"169","author":"P Kliv\u00e9nyi","year":"2006","unstructured":"Kliv\u00e9nyi P, Bende Z, Hartai Z, Penke Z, N\u00e9meth H, Toldi J, V\u00e9csei L (2006) Behaviour changes in a transgenic model of Huntington\u2019s disease. Behav Brain Res 169:137\u2013141","journal-title":"Behav Brain Res"},{"key":"573_CR26","doi-asserted-by":"crossref","first-page":"5297","DOI":"10.1523\/JNEUROSCI.15-07-05297.1995","volume":"15","author":"GB Landwehrmeyer","year":"1995","unstructured":"Landwehrmeyer GB, Standaert DG, Testa CM, Penney JB Jr, Young AB (1995) NMDA receptor subunit mRNA expression by projection neurons and interneurons in rat striatum. J Neurosci 15:5297\u20135307","journal-title":"J Neurosci"},{"key":"573_CR27","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1523\/JNEUROSCI.0116-07.2007","volume":"27","author":"Y Liu","year":"2007","unstructured":"Liu Y, Wong TP, Aarts M, Rooyakkers A, Liu L, Lai TW, Wu DC, Lu J, Tymianski M, Craig AM, Wang YT (2007) NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo. J Neurosci 27:2846\u20132857","journal-title":"J Neurosci"},{"key":"573_CR28","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1046\/j.0022-3042.2002.00805.x","volume":"80","author":"M Marchi","year":"2002","unstructured":"Marchi M, Risso F, Viola C, Cavazzani P, Raiteri M (2002) Direct evidence that release-stimulating alpha7* nicotinic cholinergic receptors are localized on human and rat brain glutamatergic axon terminals. J Neurochem 80:1071\u20131078","journal-title":"J Neurochem"},{"key":"573_CR29","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.nbd.2008.01.014","volume":"30","author":"N Masuda","year":"2008","unstructured":"Masuda N, Peng Q, Li Q, Jiang M, Liang Y, Wang X, Zhao M, Wang W, Ross CA, Duan W (2008) Tiagabine is neuroprotective in the N171-82Q and R6\/2 mouse models of Huntington\u2019s disease. Neurobiol Dis 30:293\u2013302","journal-title":"Neurobiol Dis"},{"key":"573_CR30","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/263517a0","volume":"263","author":"EG McGeer","year":"1976","unstructured":"McGeer EG, McGeer PL (1976) Duplication of biochemical changes of Huntington\u2019s chorea by intrastriatal injections of glutamic and kainic acids. Nature 263:517\u2013519","journal-title":"Nature"},{"key":"573_CR31","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/sj.npp.1300008","volume":"28","author":"FN McNamara","year":"2003","unstructured":"McNamara FN, Clifford JJ, Tighe O, Kinsella A, Drago J, Croke DT, Waddington JL (2003) Congenic D1A dopamine receptor mutants: ethologically based resolution of behavioural topography indicates genetic background as a determinant of knockout phenotype. Neuropsychopharmacology 28:86\u201399","journal-title":"Neuropsychopharmacology"},{"key":"573_CR32","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.coph.2005.12.002","volume":"6","author":"KW Muir","year":"2006","unstructured":"Muir KW (2006) Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists. Curr Opin Pharmacol 6:53\u201360","journal-title":"Curr Opin Pharmacol"},{"key":"573_CR33","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/0006-8993(82)91048-4","volume":"247","author":"MN Perkins","year":"1982","unstructured":"Perkins MN, Stone TW (1982) An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res 247:184\u2013187","journal-title":"Brain Res"},{"key":"573_CR34","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.expneurol.2005.07.004","volume":"197","author":"MT Sapko","year":"2006","unstructured":"Sapko MT, Guidetti P, Yu P, Tagle DA, Pellicciari R, Schwarcz R (2006) Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: implications for Huntington\u2019s disease. Exp Neurol 197:31\u201340","journal-title":"Exp Neurol"},{"key":"573_CR35","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/hmg\/8.3.397","volume":"8","author":"G Schilling","year":"1999","unstructured":"Schilling G, Becher MW, Sharp AH, Jinnah HA, Duan K, Kotzuk JA, Slunt HH, Ratovitski T, Cooper JK, Jenkins NA, Copeland NG, Price DL, Ross CA, Borchelt DR (1999) Intranuclear inclusions and neuritic aggregates in transgenic mice expressing mutant N-terminal fragment of huntingtin. Hum Mol Gen 8:397\u2013407","journal-title":"Hum Mol Gen"},{"key":"573_CR36","first-page":"677","volume":"23","author":"ML Schmitt","year":"1990","unstructured":"Schmitt ML, Graeff FG, Carobrez AP (1990) Anxiolytic effect of kynurenic acid microinjected into the dorsal periaqueductal gray matter of rats placed in the elevated plus-maze test. Braz J Med Biol Res 23:677\u2013679","journal-title":"Braz J Med Biol Res"},{"key":"573_CR37","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0165-0270(99)00019-9","volume":"88","author":"C Schmitz","year":"1999","unstructured":"Schmitz C, Schuster D, Niessen P, Korr H (1999) No difference between estimated mean nuclear volumes of various types of neurons in the mouse brain obtained on either isotropic uniform random sections or conventional frontal or sagittal sections. J Neurosci Methods 88:71\u201382","journal-title":"J Neurosci Methods"},{"key":"573_CR38","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.coph.2003.10.006","volume":"4","author":"R Schwarcz","year":"2004","unstructured":"Schwarcz R (2004) The kynurenine pathway of tryptophan degradation as a drug target. Curr Opin Pharmacol 4:12\u201317","journal-title":"Curr Opin Pharmacol"},{"key":"573_CR39","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.pneurobio.2009.04.005","volume":"90","author":"R Schwarcz","year":"2010","unstructured":"Schwarcz R, Guidetti P, Sathyasaikumar KV, Muchowski PJ (2010) Of mice, rats and men: revisiting the quinolinic acid hypothesis of Huntington\u2019s disease. Prog Neurobiol 90:230\u2013245","journal-title":"Prog Neurobiol"},{"key":"573_CR40","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.tins.2004.07.004","volume":"27","author":"Y Smith","year":"2004","unstructured":"Smith Y, Raju DV, Pare JF, Sidibe M (2004) The thalamostriatal system: a highly specific network of the basal ganglia circuitry. Trends Neurosci 27:520\u2013527","journal-title":"Trends Neurosci"},{"key":"573_CR41","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.freeradbiomed.2010.03.017","volume":"49","author":"C Stack","year":"2010","unstructured":"Stack C, Ho D, Wille E, Calingasan NY, Williams C, Liby K, Sporn M, Dumont M, Beal MF (2010) Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington\u2019s disease. Free Radic Biol Med 49:147\u2013158","journal-title":"Free Radic Biol Med"},{"key":"573_CR42","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/0014-2999(81)90587-2","volume":"72","author":"TW Stone","year":"1981","unstructured":"Stone TW, Perkins MN (1981) Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. Eur J Pharmacol 72:411\u2013412","journal-title":"Eur J Pharmacol"},{"key":"573_CR43","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0197-0186(01)00133-4","volume":"40","author":"RG Tavares","year":"2002","unstructured":"Tavares RG, Tasca CI, Santos CE, Alves LB, Porci\u00fancula LO, Emanuelli T, Souza DO (2002) Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes. Neurochem Int 40:621\u2013627","journal-title":"Neurochem Int"},{"key":"573_CR44","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/brain\/111.2.223","volume":"111","author":"PD Thompson","year":"1988","unstructured":"Thompson PD, Berardelli A, Rothwell JC, Day BL, Dick JP, Benecke R, Marsden CD (1988) The coexistence of bradykinesia and chorea in Huntington\u2019s disease and its implications for theories of basal ganglia control of movement. Brain 111:223\u2013244","journal-title":"Brain"},{"key":"573_CR45","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00702-009-0253-6","volume":"116","author":"E V\u00e1mos","year":"2009","unstructured":"V\u00e1mos E, V\u00f6r\u00f6s K, Z\u00e1dori D, V\u00e9csei L, Kliv\u00e9nyi P (2009a) Neuroprotective effects of probenecid in a transgenic animal model of Huntington\u2019s disease. J Neural Transm 116:1079\u20131086","journal-title":"J Neural Transm"},{"key":"573_CR46","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.neuropharm.2009.06.033","volume":"57","author":"E V\u00e1mos","year":"2009","unstructured":"V\u00e1mos E, P\u00e1rdutz \u00c1, Varga H, Boh\u00e1r Z, Tajti J, F\u00fcl\u00f6p F, Toldi J, V\u00e9csei L (2009b) l-kynurenine combined with probenecid and the novel synthetic kynurenic acid derivative attenuate nitroglycerin-induced nNOS in the rat caudal trigeminal nucleus. Neuropharmacology 57:425\u2013429","journal-title":"Neuropharmacology"},{"key":"573_CR47","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/j.1526-4610.2009.01574.x","volume":"50","author":"E V\u00e1mos","year":"2010","unstructured":"V\u00e1mos E, Fejes A, Koch J, Tajti J, F\u00fcl\u00f6p F, Toldi J, P\u00e1rdutz \u00c1, V\u00e9csei L (2010) Kynurenate derivative attenuates the nitroglycerin-induced CamKIIalpha and CGRP expression changes. Headache 50:834\u2013843","journal-title":"Headache"},{"key":"573_CR48","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/mds.870110406","volume":"4","author":"JP Vugt van","year":"1996","unstructured":"van Vugt JP, van Hilten BJ, Roos RA (1996) Hypokinesia in Huntington\u2019s disease. Mov Disord 4:384\u2013388","journal-title":"Mov Disord"},{"key":"573_CR49","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0014-2999(91)90436-T","volume":"196","author":"L V\u00e9csei","year":"1991","unstructured":"V\u00e9csei L, Beal MF (1991) Comparative behavioral and pharmacological studies with centrally administered kynurenine and kynurenic acid in rats. Eur J Pharmacol 196:239\u2013246","journal-title":"Eur J Pharmacol"},{"key":"573_CR50","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1055\/s-2007-971176","volume":"27","author":"FO Walker","year":"2007","unstructured":"Walker FO (2007) Huntington\u2019s disease. Semin Neurol 27:143\u2013150","journal-title":"Semin Neurol"},{"key":"573_CR51","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0079-6123(02)35006-4","volume":"135","author":"NJ West","year":"2002","unstructured":"West NJ (2002) Design-based stereological methods for counting neurons. Prog Brain Res 135:43\u201351","journal-title":"Prog Brain Res"},{"key":"573_CR52","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1007\/s00702-009-0263-4","volume":"116","author":"D Z\u00e1dori","year":"2009","unstructured":"Z\u00e1dori D, Kliv\u00e9nyi P, V\u00e1mos E, F\u00fcl\u00f6p F, Toldi J, V\u00e9csei L (2009a) Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies. J Neural Transm 116:1403\u20131409","journal-title":"J Neural Transm"},{"key":"573_CR53","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.pbb.2009.08.001","volume":"94","author":"D Z\u00e1dori","year":"2009","unstructured":"Z\u00e1dori D, Geisz A, V\u00e1mos E, V\u00e9csei L, Kliv\u00e9nyi P (2009b) Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington\u2019s disease. Pharmacol Biochem Behav 94:148\u2013153","journal-title":"Pharmacol Biochem Behav"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-010-0573-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-010-0573-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-010-0573-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T12:30:19Z","timestamp":1559910619000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-010-0573-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,31]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["573"],"URL":"https:\/\/doi.org\/10.1007\/s00702-010-0573-6","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,31]]}}}